Primary immunodeficiency (PID) diagnostic tests have been included in the World Health Organization (WHO)’s Essential Diagnostics List (EDL) published by WHO on July 9, 2019. The inclusion of PID diagnostics tests follows a successful joint application by IPOPI and IUIS (International Union of Immunological Societies) which was supported by numerous other organisations and societies in the field.
This achievement is an important step in the international advocacy IPOPI leads to ensure awareness about PIDs, as this list provides “evidence-based guidance and set a reference for the development or update of national lists of essential in vitro diagnostic tests”. IPOPI through its work on this list hopes to facilitate the advocacy led by its national member organisations in collaboration with national experts to ensure that the diagnostics needed for PIDs are available at national level.
The diagnostics that have been recognised as essential for the diagnosis of PIDS by the WHO are the following: immunoglobulin plasma levels (IgA, IgM, IgG) to identify patients with low Ig levels and monitor replacement, lymphocyte subtype enumeration (CD4, CD8, CD20, NK (CD16/56)) to aid in the diagnosis of primary and secondary immunodeficiencies, HIV ½ antibody for the differential diagnosis of PIDs, complete blood count to detect a wide range of disorders amongst which PIDs.